Avalon Ventures launches 3 biotech startups with GSK
Avalon and GSK's three new startups - Adrenergics, CadheRx Therapeutics and Calporta Therapeutics will each receive up to $10 million in Series A financing.
Avalon and GSK's three new startups - Adrenergics, CadheRx Therapeutics and Calporta Therapeutics will each receive up to $10 million in Series A financing.